Satralizumab: First Approval - SAkuraStar and SAkuraSky clinical trial video abstracts

SAKuraStar (NCT02073279) and SAkuraSky (NCT02028884) are two pivotal phase 3 randomized, placebo-controlled clinical trials that led to the first approval of satralizumab, a humanized anti-interleukin-6 (IL-6) receptor monoclonal recycling antibody, for the treatment of neuromyelitis optica spectrum disorder (NMOSD).

These video abstracts of SAKuraStar and SAkuraSky provide

· a brief overview of the pathophysiology of NMO and NMOSD,

· the mechanism of action of satralizumab in patients with this disorder and

· the key efficacy and tolerability outcomes for subcutaneous satralizumab 120 mg administered as monotherapy (in SAkuraStar) or as add-on therapy to baseline immunosuppressant therapy (SAkuraSky) in patients with NMO or NMOSD.

These video abstracts, which have been peer reviewed and were uploaded to Figshare after the satralizumab AdisInsight Report was published, are sponsored by Roche.